Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced results from a real-world analysis showing that patients with tardive dyskinesia remained on INGREZZA treatment longer than those taking AUSTEDO XR. The findings were presented at the Academy of Managed Care Pharmacy 2026 Annual Meeting in Nashville.

The retrospective claims analysis examined 2,988 patients split equally between INGREZZA and AUSTEDO XR treatment groups. Using propensity score matching, researchers created balanced cohorts accounting for baseline demographics, comorbidities, psychiatric conditions and antipsychotic use.

Over six months, 55.6% of patients persisted with INGREZZA compared to 48.1% who continued AUSTEDO XR treatment. The switching rate to other tardive dyskinesia therapies was 7.7% for INGREZZA patients versus 11.2% for AUSTEDO XR patients.

The analysis used IQVIA's U.S. Longitudinal Access and Adjudication Data from September 2022 to March 2025. Eligible patients had pharmacy claims during both baseline and follow-up periods and at least one claim with a tardive dyskinesia diagnosis.

"Treatment discontinuation is common in psychiatric populations, and interruption of VMAT2 inhibitor therapy can lead to recurrence of tardive dyskinesia symptoms," said Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences.

The median time to treatment discontinuation or switching was 129 days for AUSTEDO XR patients, while the median was not reached for INGREZZA patients, indicating more than 180 days.

INGREZZA is approved by the U.S. Food and Drug Administration for treating adults with tardive dyskinesia and chorea associated with Huntington's disease. The drug selectively inhibits vesicular monoamine transporter 2 with no required titration.